201 related articles for article (PubMed ID: 25001880)
1. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
Depta JP; Lenzini PA; Lanfear DE; Wang TY; Spertus JA; Bach RG; Cresci S
Pharmacogenomics J; 2015 Feb; 15(1):20-5. PubMed ID: 25001880
[TBL] [Abstract][Full Text] [Related]
2. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
[TBL] [Abstract][Full Text] [Related]
3. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.
Cresci S; Depta JP; Lenzini PA; Li AY; Lanfear DE; Province MA; Spertus JA; Bach RG
Circ Cardiovasc Genet; 2014 Jun; 7(3):277-86. PubMed ID: 24762860
[TBL] [Abstract][Full Text] [Related]
5. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.
Evanchan J; Donnally MR; Binkley P; Mazzaferri E
Clin Cardiol; 2010 Mar; 33(3):168-71. PubMed ID: 20235209
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB
Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
[TBL] [Abstract][Full Text] [Related]
9. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
[TBL] [Abstract][Full Text] [Related]
10. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
[TBL] [Abstract][Full Text] [Related]
11. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
12. [Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
Xu JJ; Tang XF; Song Y; Xu N; Yao Y; Wu Y; Zhang J; Gao Z; Chen J; Gao RL; Yang YJ; Yuan JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Feb; 45(2):116-120. PubMed ID: 28260316
[No Abstract] [Full Text] [Related]
13. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
[TBL] [Abstract][Full Text] [Related]
15. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Stockl KM; Le L; Zakharyan A; Harada AS; Solow BK; Addiego JE; Ramsey S
Arch Intern Med; 2010 Apr; 170(8):704-10. PubMed ID: 20421557
[TBL] [Abstract][Full Text] [Related]
16. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Martínez-Quintana E; Medina-Gil JM; Rodríguez-González F; Garay-Sánchez P; Limiñana JM; Saavedra P; Tugores A
J Clin Pharmacol; 2014 Aug; 54(8):843-9. PubMed ID: 24504666
[TBL] [Abstract][Full Text] [Related]
17. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
[TBL] [Abstract][Full Text] [Related]
18. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
[TBL] [Abstract][Full Text] [Related]
19. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
20. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
